Every material Form 8-K Milestone Pharmaceuticals Inc. has filed with the SEC since August 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 23, 2026, Milestone Pharmaceuticals received a Nasdaq notice that its common shares fell below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 21, 2027 to regain compliance, and Nasdaq says the notice has no present impact on the listing, though failure to comply could lead to delisting.
Nasdaq notice dated October 23, 2026 cites Listing Rule 5450(a)(1) for the $1.00 minimum bid price.
Compliance period runs 180 calendar days, until April 21, 2027, requiring a closing bid of $1.00 or more for at least 10 consecutive business days.
If not compliant, the company may seek a transfer to the Nasdaq Capital Market, which requires a $5,000 application fee, or pursue a reverse stock split.
The filing states there can be no assurance the shares will remain listed.
Milestone Pharmaceuticals announced that China's National Medical Products Administration approved etripamil nasal spray for paroxysmal supraventricular tachycardia in adults, the first approval of the drug outside the United States. The approval triggers a $2.0 million milestone payment to Milestone and makes it eligible for up to $98.0 million more in milestones and tiered royalties of up to 18% from Everest Medicines, its Greater China licensee.
NMPA approval announced September 3, 2026; first regulatory approval of etripamil outside the United States
$2.0 million milestone payment to Milestone triggered by the approval
Everest Medicines holds an exclusive Greater China license and will lead commercialization
Milestone is eligible for up to $98.0 million in commercial and development milestones and royalties up to 18%
Milestone Pharmaceuticals reported second-quarter 2026 results with first product revenue of $559,000 for CARDAMYST, which launched in mid-February 2026. The net loss widened to $28.6 million, or $0.21 per share, from $13.0 million, or $0.20 per share, a year earlier, driven by higher selling, general and administrative expense tied to the launch. The company said its $170.6 million in cash and short-term investments is expected to fund operations into the second half of 2027.
Q2 2026 product revenue was $559,000, compared with none in Q2 2025; six-month product revenue was $797,000.
Q2 2026 net loss was $28.6 million, or $0.21 per share, versus $13.0 million, or $0.20 per share, in Q2 2025.
Selling, general and administrative expense rose to $22.6 million from $8.9 million, which the company attributed to CARDAMYST launch costs.
Cash, cash equivalents and short-term investments were $170.6 million at June 30, 2026, versus $106.0 million at December 31, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Milestone Pharmaceuticals Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →